Biogen Idec Announces Layoffs, Property Sales in Wake of Tysabri Withdrawal

Drug Industry Daily
KEYWORDS Markets / Recall
A A

With the future of its withdrawn multiple sclerosis drug Tysabri still unclear, Biogen Idec plans to lay off 650 employees, sell its San Diego manufacturing plant and channel the savings from those moves into drug development.

To View This Article:

Login

Subscribe To Drug Industry Daily